美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Kalaris Therapeutics Inc.

6.99

+0.29004.33%

盤後：6.990.00000.00%16:05 EDT

成交量：1.92萬

成交額：13.50萬

市值：1.31億

市盈率：-0.67

高：7.31

開：6.52

低：6.52

收：6.70

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Kalaris Therapeutics Inc.

交易所：

NASDAQ

成立時間：

2019

員工人數：

14

公司地址：

628 Middlefield Road,Palo Alto,California,United States

官網：

http://www.allovir.com

郵編：

94301

電話：

- -

傳真：

- -

簡介：

Kalaris Therapeutics, Inc.成立於2013年8月16日，是特拉華州的一家有限責任公司。該公司是一家領先的臨床晚期細胞治療公司，開發高度創新的異基因T細胞療法來治療和預防毀滅性的病毒性疾病。該公司的創新和專有的病毒特異性T細胞（VST）治療平台能夠產生現成的VST，旨在恢復T細胞缺陷患者的免疫力。

董事

名稱

職位

David Hallal

Chief Executive Officer and Director

Vikas Sinha

President, Chief Financial Officer and Director

Ansbert Gadicke

Director

Diana Brainard

Director

Jeffrey S. Bornstein

Director

John Wilson

Director

Juan Vera

Director

Malcolm Brenner

Director

Morana Jovan Embiricos

Director

股東

名稱

職位

David Hallal

Chief Executive Officer and Director

Vikas Sinha

President, Chief Financial Officer and Director

Agustin Melian

Chief Medical Officer

Ann Leen

Chief Scientific Officer

Brett Hagen

Chief Accounting Officer

Edward Miller

General Counsel

Ercem Atillasoy

Chief Regulatory and Safety Officer

Jeroen van Beek

Chief Commercial Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/KLRS/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":6.99,"timestamp":1744920000000,"preClose":6.7,"halted":0,"volume":19203,"hourTrading":{"tag":"盘后","latestPrice":6.99,"preClose":6.99,"latestTime":"16:05 EDT","volume":23,"amount":160.77,"timestamp":1744920312165},"delay":0,"floatShares":5446509,"shares":18702413,"eps":-10.437743,"marketStatus":"休市中","change":0.29,"latestTime":"04-17 16:00:00 EDT","open":6.52,"high":7.31,"low":6.52,"amount":135039.7002,"amplitude":0.11791,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.437743,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":6.7,"postHourTrading":{"tag":"盘后","latestPrice":6.99,"preClose":6.99,"latestTime":"16:05 EDT","volume":23,"amount":160.77,"timestamp":1744920312165},"volumeRatio":0.1452943340841707},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":5446509,"roa":"-681.04%","roe":"--","lyrEps":-10.437743,"volumeRatio":0.1452943340841707,"shares":18702413,"dividePrice":0,"high":7.31,"amplitude":0.11791,"preClose":6.7,"low":6.52,"week52Low":5.865,"pbRate":"-1.35","week52High":24.15,"institutionHeld":0,"latestPrice":6.99,"eps":-10.437743,"divideRate":0,"volume":19203,"delay":0,"ttmEps":-10.437743,"open":6.52,"prevYearClose":9.66,"prevWeekClose":7.23,"prevMonthClose":8.03,"prevQuarterClose":8.03,"fiveDayClose":7.31,"twentyDayClose":11.4,"sixtyDayClose":9.2},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1900954228,"yearFounded":2019,"employeeNum":14,"address":"628 Middlefield Road,Palo Alto,California,United States","zipCode":"94301"},"stockCompanyDetail":{"websiteUrl":"http://www.allovir.com","stockEarnings":[{"period":"1week","weight":-0.0438},{"period":"1month","weight":-0.2875},{"period":"3month","weight":-0.2468},{"period":"6month","weight":-0.6069},{"period":"1year","weight":-0.5985},{"period":"ytd","weight":-0.2764}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Kalaris Therapeutics, Inc.成立於2013年8月16日，是特拉華州的一家有限責任公司。該公司是一家領先的臨床晚期細胞治療公司，開發高度創新的異基因T細胞療法來治療和預防毀滅性的病毒性疾病。該公司的創新和專有的病毒特異性T細胞（VST）治療平台能夠產生現成的VST，旨在恢復T細胞缺陷患者的免疫力。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.05141},{"month":2,"riseRate":0.8,"avgChangeRate":0.066777},{"month":3,"riseRate":0.2,"avgChangeRate":-0.236404},{"month":4,"riseRate":0.4,"avgChangeRate":-0.104038},{"month":5,"riseRate":0.25,"avgChangeRate":-0.027821},{"month":6,"riseRate":0.25,"avgChangeRate":-0.072525},{"month":7,"riseRate":0.5,"avgChangeRate":0.034661},{"month":8,"riseRate":0.8,"avgChangeRate":0.189154},{"month":9,"riseRate":0.6,"avgChangeRate":-0.014837},{"month":10,"riseRate":0.2,"avgChangeRate":-0.070906},{"month":11,"riseRate":0.6,"avgChangeRate":0.030408},{"month":12,"riseRate":0,"avgChangeRate":-0.295433}],"exchange":"NASDAQ","name":"Kalaris Therapeutics Inc.","nameEN":"Kalaris Therapeutics Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":{"directors":[{"name":"David Hallal","position":"Chief Executive Officer and Director"},{"name":"Vikas Sinha","position":"President, Chief Financial Officer and Director"},{"name":"Ansbert Gadicke","position":"Director"},{"name":"Diana Brainard","position":"Director"},{"name":"Jeffrey S. Bornstein","position":"Director"},{"name":"John Wilson","position":"Director"},{"name":"Juan Vera","position":"Director"},{"name":"Malcolm Brenner","position":"Director"},{"name":"Morana Jovan Embiricos","position":"Director"}],"executives":[{"name":"David Hallal","position":"Chief Executive Officer and Director"},{"name":"Vikas Sinha","position":"President, Chief Financial Officer and Director"},{"name":"Agustin Melian","position":"Chief Medical Officer"},{"name":"Ann Leen","position":"Chief Scientific Officer"},{"name":"Brett Hagen","position":"Chief Accounting Officer"},{"name":"Edward Miller","position":"General Counsel"},{"name":"Ercem Atillasoy","position":"Chief Regulatory and Safety Officer"},{"name":"Jeroen van Beek","position":"Chief Commercial Officer"}]},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-07","symbol":"KLRS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1741323600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2025-01-16","symbol":"KLRS","defaultRemindTime":1737037800000,"type":"split","dateTimestamp":1737003600000,"forFactor":23,"toFactor":1,"ratio":23},{"market":"US","date":"2024-11-12","symbol":"KLRS","fiscalQuarterEnding":"2024/09","expectedEps":-0.14,"name":null,"time":"盤後","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.04},{"market":"US","date":"2024-08-09","symbol":"KLRS","fiscalQuarterEnding":"2024/06","expectedEps":-0.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"pre","actualEps":-0.05},{"market":"US","date":"2024-05-13","symbol":"KLRS","fiscalQuarterEnding":"2024/03","expectedEps":-0.16,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715572800000,"reportTimeType":"post","actualEps":-0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2025-04-17","current":-1.811647,"percent":0.882353,"low":-2.839148,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"high":-1.746752,"avg":-2.113287,"sd":0.282591,"marketCap":125306167},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167}],"updateTime":1745070239795}}}